STAAR Surgical is trading at $30.26, up 11.37% in after-hours trading on November 4, 2026, following third-quarter results that beat expectations.

  • Revenue was $83.4 million and adjusted EPS was $0.28.
  • Reported sales declined about 12% year over year; excluding the prior-year $25.9 million deferred China revenue comparison, management said sales grew 21%.
  • The company reaffirmed its full-year outlook, supporting the positive earnings reaction.